Progress in post-marketing clinical researches for Nuplazid
Parkinson's disease psychosis(PDP)is a common non-motor manifestation of Parkinson's disease.Before the mar-keting of Nuplazid,no drug is readily available for treating PDP in clinical practices.Its mechanism of action lies in regulating the binding activity of reverse agonists and antagonists of serotonin 5-HT2A receptor.Domestic scholars have systematically com-piled the pharmaceutical and clinical data of this drug before its launch.However,there is a lack of clinical researches after its launch.This review summarized the latest studies of Nuplazid after its launch.The relevant issues were discussed to offer reason-able suggestions for introducing or replicating its analogues.
NETL
NSTL
万方数据
